Imprint
Koji Kawakami, Wen Yun, Michael Untch(Helios Kliniken), Frederik Wenz, Brigitte Rack(LMU Klinikum), Peter Dall, Hiroshi Ishiguro, Christian Jackisch(Goethe University Frankfurt), Elmar Stickeler(Universitätsklinikum Aachen), Bernd Gerber, Sabina Berktold, Nadia Harbeck(Breast Center), Ingo Bauerfeind, Petra Klose(University of Duisburg-Essen), Ido Wolf, Holm Eggemann, Meghana V. Trivedi(University of Houston), Atanas Ignatov(Otto-von-Guericke-Universität Magdeburg), Shira Peleg Hasson, Tamar Rubinek(Tel Aviv University), Peter Hass, Silke Steinbach(Krankenhaus vom Roten Kreuz), Evandro de Azambuja(Université Libre de Bruxelles), Anna Paul, Christina Böhner, Andreas Schneeweiß(German Cancer Research Center), Ayotunde J. Fasunla, Petra Wolf, Rachel Schiff, Ana Catarina Pinto, Martine Piccart-Gebhart, Jian Li, Silke Lange, Roland Stabenow(Fondazione IRCCS Istituto Nazionale dei Tumori), Sherko Kümmel(Kliniken Essen-Mitte), Florian Schütz(Heidelberg University), Gustav Dobos(University of Duisburg-Essen), Walter Hundt, Petra Voiß, Serban-Dan Costa, Cornelia Liedtke, Gϋnter von Minckwitz(German Breast group), Shiro Hinotsu(Sapporo Medical University), Shota Hamada, Masakazu Toi, Mario Giuliano, L Ryvo, Friedrich Wilhelm Röhl, Caterina Fontanella
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k